Introduction {#section1-ijao.5000583}
============

Infective endocarditis (IE) is a serious heart disease caused by microorganisms that enter the bloodstream and settle on the endocardium, heart valves or intracardiac devices. The cardiac effects of IE may include severe valve dysfunction and myocardial abscesses, which may finally lead to severe congestive heart failure. Therefore, depending on the causative microbes (e.g., staphylococci, enterococci, streptococci) and the clinical symptoms, valve replacement may be indicated for these patients ([@bibr1-ijao.5000583], [@bibr2-ijao.5000583]). Beside the described intracardiac effects, IE patients are at high risk for developing systemic inflammatory response and septic shock as a result of the bacterial spreadout from valve vegetations. Therefore, a surgical procedure (most often replacement of the affected valve) together with cardiopulmonary bypass (CPB) in a patient with an underlying IE disease represents an intervention with increased risks. The combination of surgical trauma, bacterial spreadout and artificial CPB surfaces results in a release of key inflammatory mediators such as IL-6 and IL-8. This may finally lead to an overshooting systemic hyperinflammatory state, frequently resulting in hemodynamic instability that in turn may induce organ dysfunction such as respiratory failure, acute kidney injury, intestinal ischemia and/or cognitive dysfunction ([@bibr3-ijao.5000583]). Of note, in case of prolonged CPB surgery, the risk of developing severe systemic inflammatory response syndrome (SIRS) postoperatively may increase even more. Postoperative therapeutic management of these patients includes an appropriate anti-infective therapy in combination with therapeutic approaches maintaining vital organ function.

Since inflammatory mediators are key triggers of inflammation and post-CPB SIRS, intra- or postoperative removal of such mediators from blood using blood purification with a cytokine adsorber has previously been described as an useful approach to control these hyperinflammatory processes, to restore immune homeostasis and potentially to prevent post-CPB SIRS and multiple organ dysfunction syndrome (MODS) ([@bibr4-ijao.5000583], [@bibr5-ijao.5000583]). Currently, the device most used as an adjunctive treatment to standard therapy in subjects suffering from SIRS, severe sepsis or septic shock to support the removal of cytokines as well as other inflammatory mediators via direct whole blood hemoadsorption is CytoSorb.

Cytosorb (CytoSorbents Corporation) is a polymer bead-based cytokine hemoadsorption cartridge approved in Europe since 2011 that can be used in combination with conventional hemodialysis machines or with CPB systems. In general, with more than 17,000 single treatments performed worldwide to date, CytoSorb application can be considered a safe and biocompatible therapeutic intervention. In this paper we describe the intraoperative application of CytoSorb hemoadsorption in 39 patients during CPB surgery due to IE.

Patients and methods {#section2-ijao.5000583}
====================

This case series was conducted in the 12-bed adult cardiothoracic surgery Intensive Care Unit (ICU) at the University Hospital Ulm, Germany. Informed consent for retrospective data evaluation was obtained from all patients or their relatives. From September 2013 until August 2016 we treated and monitored 39 consecutive patients undergoing cardiac surgery with CPB due to acute infective endocarditis. Patient characteristics, diagnoses and individual surgical procedure details are outlined in [Table I](#table1-ijao.5000583){ref-type="table"}. Briefly, all patients underwent urgent or emergency cardiac surgery procedures with CPB application ([Tab. I](#table1-ijao.5000583){ref-type="table"}). A CytoSorb adsorber cartridge was integrated in a parallel circuit in post-hemofilter position within the extracorporeal CPB circuit. Anticoagulation was achieved using heparin as standard anticoagulant according to routine procedure. Blood flow rates through the adsorber were kept between 200 and 400 mL/min and patients consistently received only CytoSorb treatment during surgery for the entire CPB time and without exchange of the adsorber. Treatment durations are depicted in [Table I](#table1-ijao.5000583){ref-type="table"}. Hemodynamic management with catecholamines (i.e., epinephrine, norepinephrine) and volume therapy was performed according to the standard of care protocol. To assess the therapeutic impact of the hemoadsorption treatment we measured laboratory parameters of inflammation (i.e., IL-6 and IL-8) hemodynamics (vasopressor dose, MAP), metabolic variables (lactate, base excess) as well as the extent of postoperative organ support (mechanical ventilation, ECMO, CRRT). Furthermore, we evaluated severity of illness in all patients preoperatively using the European System for Cardiac Operative Risk Evaluation (EuroSCORE II) ([@bibr6-ijao.5000583]) and additionally assessed the postoperative and 24-hour postoperative Acute Physiology and Chronic Health Evaluation (APACHE II score). ICU length of stay as well as ICU and hospital survival were obtained as outcome parameters.

###### 

Patient Characteristics, Surgery Details, Treatment Modalities and Patient Outcome (Hemoadsorption Group)

![](10.5301_ijao.5000583-table1)

  Case   Age   Gender   BMI    Diagnosis                   Microbiological findings               Operation procedure                 Emergency   Euro SCORE II   CPB time (min)   X clamp time (min)   CytoSorb treatment time (min)   APACHE II postop   APACHE II 24h postop   Mechanical ventilation (days)   ECMO (days)   CRRT (days)   Hydrocortisone   ICU LOS (d)   ICU survival   Hospital survival
  ------ ----- -------- ------ --------------------------- -------------------------------------- ----------------------------------- ----------- --------------- ---------------- -------------------- ------------------------------- ------------------ ---------------------- ------------------------------- ------------- ------------- ---------------- ------------- -------------- -------------------
  1      43    M        20.7   AV Endocarditis             Staph. aureus                          Re-Re ARR, Mechanoconduit           No          18.96           253              151                  253                                                                       1                                             2             No               12            Yes            Yes
  2      73    F        24.8   AV Endocarditis             Streptococcus mitis/cristatis          Re-AVR                              No          31.14           114              69                   115                             33                 28                     1                                                           No               7             Yes            Yes
  3      75    F        20.8   AV Endocarditis                                                    Bio-Conduit ARR, CABG               Yes         96.73           445              250                  445                             46                                        1                               1             No            1                No            No             
  4      67    M        21.3   AV Endocarditis             Abiotropha defectiva                   AVR, abscess removal, CABG-RCA      Yes         12.75           138              100                  138                             26                 14                     1                                                           No               7             Yes            Yes
  5      75    M        28.7   AV Endocarditis             Staph.aureus                           AVR                                 Yes         4.96            71               49                   72                                                                        1                                                           No               9             Yes            Yes
  6      37    M        36.0   AV Endocarditis             Staph. aureus, Stertococcus pyogenes   AVR                                 Yes         16.68           112              78                   112                             24                 24                     12                                                          Yes              19            Yes            Yes
  7      52    M        26.5   MV + AV Endocarditis        Streptococcus mitis                    MVR, AVR, ARRec, SCAE               No          9.01            200              145                  200                                                                       1                                                           Yes              11            Yes            Yes
  8      69    F        49.5   MV Endocarditis             Staph. aureus                          MVR                                 Yes         64.18           115              70                   115                             32                 26                                                                                 No               32            No             No
  9      62    M        32.3   MV Endocarditis             Streptococcus viridans                 MVR                                 Yes         48.24           171              107                  142                             31                 21                     2                                             3             Yes              6             Yes            Yes
  10     75    M        25.1   MV + AV Endocarditis        Streptococcus mitis                    AVR, MVR                            Yes         5.22            138              104                  138                             24                 12                     1                                                           No               3             Yes            Yes
  11     75    F        22.8   AV Endocarditis                                                    AVR                                 Yes         9.62            88               60                   88                              30                 15                     1                                                           No               4             Yes            Yes
  12     64    M        26.9   MV Endocarditis             Streptococcus agalactiae               MVR                                 Yes         2.21            117              90                   116                             28                 20                     2                                                           No               4             Yes            Yes
  13     33    M        25.7   TK Endocarditis             Staph. aureus, fungi                   MICTKR                              No          4.43            101              61                   102                             31                 17                     1                                                           No               5             Yes            Yes
  14     38    M        19.8   MV Endocarditis             Streptococcus agalactiae               MIC MVR                             Yes         6.2             109              75                   91                              33                 20                     1                                                           No               4             Yes            Yes
  15     77    F        30.1   MV Endocarditis             Streptococcus bovis                    MVR                                 Yes         53.17           122              89                   122                             37                 33                     4                                             3             Yes              4             No             No
  16     60    M        30.0   AV Endocarditis                                                    AVR, MKR, TKR, RFA                  Yes         12.83           204              145                  205                             32                 31                     2                                             4             Yes              6             Yes            Yes
  17     58    M        28.4   MV Endocarditis             Streptococcus dysgalactiae             MVR, 2x CABG                        Yes         12.03           132              90                   133                             30                 12                     1                                                           No               6             Yes            Yes
  18     79    F        26.8   MV Endocarditis             Streptococcus mitis                    MVR                                 No          3.99            66               45                   64                              28                 18                     3                                                           No               4             Yes            Yes
  19     62    F        27.7   MV Endocarditis             Staph. aureus                          MVR                                 Yes         31.46           141              83                   141                             33                 28                     7                                             6             Yes              13            Yes            Yes
  20     73    M        23.5   AV Endocarditis             Propionibacterium                      AVR                                 No          4.15            101              67                   102                             32                 11                     1                                                           No               4             Yes            No
  21     30    M        26.2   AV Endocarditis             Staph. aureus                          Re-AVR, TKE, VA ECMO                Yes         31.69           280              129                  282                             30                 30                     2                               2             1             Yes              2             No             No
  22     76    F        29.3   MV Endocarditis             Enterococcus faecalis                  MVR                                 No          74.69           159              69                   160                             33                 30                     8                               4             1             Yes              8             No             No
  23     57    M        27.1   MV Endocarditis             Streptococcus agalactiae               MVR                                 Yes         33.1            128              95                   128                                                27                     2                                             3             Yes              11            Yes            Yes
  24     51    F        23.4   AV Endocarditis             Streptococcus mitis                    AVR, SCAE                           Yes         4.49            224              161                  224                             25                 14                     1                                                           No               3             Yes            Yes
  25     56    M        27.0   AV Endocarditis             Staphylococcus aureus                  bio Bentall, CABG, SCAE             No          9.62            340              257                  340                             22                 10                     8                                                           No               8             Yes            Yes
  26     37    M        25.0   AV Endocarditis             Streptokokken                          Bentall OP, SCAE, abscess removal   No          9.01            180              132                  180                                                                       2                                                           No               5             Yes            Yes
  27     59    M        24.6   AV Endocarditis             Staph aureus                           Re-AVR, RFA, LAA closure            No          60.49           128              74                   128                             30                 23                     3                                             2             Yes              3             Yes            No
  28     48    M        23.4   AV Endocarditis             Enterococcus faecalis                  mAVR, mMVR, SCAE                    Yes         11              148              126                  148                             30                 16                     1                                                           No               4             Yes            Yes
  29     67    F        34.5   MV + AV Endocarditis                                               RE AVR, MVR, ARR                    No          50.07           302              210                  302                             36                 33                     2                               2             2             Yes              2             No             No
  30     60    F        44.5   AV Endocarditis             Staph. aureus                          Re-AVR                              No          22.23           125              84                   125                             32                 13                     3                                                           No               6             Yes            Yes
  31     77    M        23.7   AV Endocarditis             Enterococcus faecalis                  AVR, TKR, RFA, VA ECMO              Yes         78.23           208              114                  208                             39                 36                     7                               2             7             Yes              7             No             No
  32     51    M        30.5   AV Endocarditis             Streptococcus sanguinis                AVR, SCAE                           Yes         16.17           117              94                   116                             32                 29                     1                                                           No               5             Yes            Yes
  33     46    M        29.3   AV Endocarditis             Staph. aureus                          AVR                                 No          62.96           157              87                   157                                                                       5                               5             5             No               5             No             No
  34     56    M        22.6   AV Endocarditis             Streptococcus agalactiae               AVR                                 No          2.15            90               61                   90                              26                 10                     1                                                           No               3             Yes            Yes
  35     61    M        26.6   AV prothesis Endocarditis                                          Re-AVR                              No          5.2             134              96                   134                             19                 5                      1                                                           No               4             Yes            Yes
  36     68    M        39.2   AV Endocarditis                                                    AVR                                 Yes         5.67            82               54                   82                                                                        3                                             3             No               4             Yes            Yes
  37     70    M        33.8   AV Endocarditis             Streptococcus mitis                    AVR                                 Yes         28.3            110              73                   110                                                                       1                                             3             No               10            Yes            Yes
  38     61    M        16.9   MV Endocarditis             No microbiologiacal finding            MVR, ACVB                           Yes         4.99            104              66                   105                                                                       2                                                           No               2             Yes            Yes
  39     75    F        39.7   MV Endocarditis             Staphylococcus aureus                  MVR                                 No          55.76           131              87                   132                             31                 19                     3                                             3             No               11            Yes            Yes

ARR = aortic root replacement; AVR = aortic valve replacement; MVR = mitral valve replacement; ARRec = aortic root reconstruction; TKR = tricuspid valve replacement.

In addition we retrieved clinical parameters and outcome data from a historical control group (from the years 2013 and 2014) of patients with infective endocarditis who had surgery with CPB but without CytoSorb hemoadsorption intraoperatively. However, in this group perioperative cytokine levels were not routinely measured and are therefore not available. The data of this comparative historical group are given in [Table II](#table2-ijao.5000583){ref-type="table"}.

###### 

Patient characteristics, surgery details, treatment modalities and patient outcome (comparative historical group)

![](10.5301_ijao.5000583-table2)

  Case    Age   Gender   BMI   Diagnosis                                    Microbiological findings                            Operation procedure          Emergency   EuroSCORE II   CPB time (min)   X clamp time (min)   Mechanical ventilation (days)   ECMO (days)   CRRT (days)   Hydrocortisone   ICU LOS (d)   ICU survival   Hospital survival
  ------- ----- -------- ----- -------------------------------------------- --------------------------------------------------- ---------------------------- ----------- -------------- ---------------- -------------------- ------------------------------- ------------- ------------- ---------------- ------------- -------------- -------------------
  Con01   57    M        31    MV endocarditis                              Staph. Aureus                                       MVR                          Yes         3.3            100              59                   3                                                           No               21            Yes            Yes
  Con02   72    M        26    AV endocarditis                              Granulicatella adiacens                             aortic root conduit repair   Yes         26.0           202              134                  26                              7             30            Yes              96            No             No
  Con03   79    M        27    AV endocarditis                              Enterococcus faecalis                               AVR                          No          23.0           190              86                   3                                             10            No               9             Yes            Yes
  Con04   65    F        24    MV endocarditis                              Streptococcus pneumoniae                            MVR                          Yes         3.4            232              75                   7                                                           No               6             Yes            Yes
  Con05   75    M        23    MV endocarditis                              Streptococcus mitis                                 MVR, TV repair               No          14.9           127              84                   7                                                           Yes              9             Yes            Yes
  Con06   64    M        30    AV prothesis endocarditis                    none                                                AVR                          Yes         25.9           138              96                   1                                             4             No               10            Yes            Yes
  Con07   62    M        28    AV endocarditis                              Streptococcus gallolyticus                          AVR                          No          5.3            92               63                   1                                                           No               6             Yes            Yes
  Con08   59    M        23    MV endocarditis                              Staphylococcus aureus                               MV repair                    Yes         2.4            110              67                   1                                                           No               5             Yes            Yes
  Con09   56    M        26    AV and MV endocarditis                       Streptococcus mitis                                 AV and MVR                   No          2.2            142              105                  1                                                           No               4             Yes            Yes
  Con10   76    M        31    AV prothesis endocarditis                    Enterococcus faecalis                               AVR                          No          8.6            115              86                   6                                             2             No               14            Yes            Yes
  Con11   72    F        33    MV prothesis endocarditis, AV endocarditis   Corynebacterium species                             MVR, AVR                     Yes         33.9           231              167                  8                               8             8             Yes              8             No             No
  Con12   85    F        35    AV prothesis endocarditis                    Aerococcus urinae                                   AVR                          No          16.1           143              103                  1                                             4             No               7             Yes            Yes
  Con13   80    M        23    MV endocarditis                              Citrobacter koseri                                  MVR, AVR                     No          7.5            145              106                  4                                                           Yes              14            Yes            Yes
  Con14   79    F        28    MV endocarditis                              Staphylococcus aureus                               MVR                          No          24.6           164              106                  2                                             7             Yes              8             Yes            Yes
  Con15   72    F        28    AV endocarditis                              Escherichia coli                                    AVR                          No          4.0            39               27                   1                                                           No               9             Yes            Yes
  Con16   77    M        23    AV endocarditis                              Staphylococcus haemolyticus                         AVR                          No          10.9           116              81                   1                                                           No               3             Yes            Yes
  Con17   88    M        27    AV endocarditis                              Citrobacter koseri                                  AVR                          No          12.0           105              66                   1                                                           No               5             Yes            Yes
  Con18   82    F        21    MV endocarditis                              Escherichia coli                                    MVR                          No          15.6           125              90                   2                                             5             Yes              12            Yes            Yes
  Con19   75    F        21    MV endocarditis                              Steptococcus mutans                                 MVR                          No          11.8           120              80                   1                                             3             No               4             Yes            Yes
  Con20   51    M        29    MV endocarditis                              Staphylococcus lugdunensis, Enterococcus faecalis   MVR                          No          3.3            108              72                   2                                                           No               6             Yes            Yes
  Con21   37    M        26    TV endocarditis                              Staphylococcus aureus                               TVR                          No          1.3            78               54                   5                                                           No               10            Yes            Yes
  Con22   63    M        30    MV and Av endocarditis                       Enterococcus faecalis                               MV and AVR                   No          9.5            138              108                  2                                                           Yes              2             Yes            Yes
  Con23   41    M        20    MV endocarditis                              Streptococcus mitis                                 MVR                          No          1.7            179              146                  1                                                           No               4             Yes            Yes
  Con24   76    F        32    MV endocarditis                              Streptococcus agalctiae                             MVR                          No          14.2           93               66                   1                                                           No               7             Yes            Yes
  Con25   82    M        21    AV prothesis endocarditis                    Enterococcus faecalis                               AVR                          No          13.2           182              82                   2                                                           No               10            Yes            Yes
  Con26   38    M        26    AV endocarditis                              none                                                AVR                          No          2.2            73               51                   1                                                           No               3             Yes            Yes
  Con27   61    M        25    AV prothesis endocarditis                    Corynebacterium species                             AVR                          No          6.9            96               53                   3                                                           No               4             Yes            Yes
  Con28   36    M        28    TV endocarditis                              Staphylococcus aureus                               TVR                          Yes         19.2           122              58                   41                                            46            Yes              57            Yes            Yes

ARR = aortic root replacement; AVR = aortic valve replacement; MVR = mitral valve replacement; ARRec = aortic root reconstruction; TKR = tricuspid valve replacement.

Of note, all sets of data were statistically analyzed and graphically presented by means of the GraphPad Prism 7.01 software showing the median and interquartile range.

Results {#section3-ijao.5000583}
=======

Preoperative EuroSCORE II values in the CytoSorb group were rather heterogeneous, ranging between 2.2 and 96.7 (median 11). In the CytoSorb group, the median EuroSCORE II values for ICU survivors (n = 31) and ICU non-survivors (n = 8) were 11 and 64, respectively. In the comparative historical control group, the median EuroSCORE II values for ICU survivors (n = 26) and ICU non-survivors (n = 2) were 9 and 30, respectively. CPB times and X clamp times are depicted in [Table I](#table1-ijao.5000583){ref-type="table"}. All patients in the CytoSorb group obtained CytoSorb treatments that ranged from 64 up to 445 minutes duration (median 132 minutes). All patients showed a marked intraoperative increase of inflammatory mediators IL-6 and IL-8 followed by peak levels measured directly after completion of the surgical procedure. This was followed by a clear decrease in levels of IL-6 and IL-8 on postoperative day 1 and a return to preoperative baseline levels on postoperative day 3 ([Fig. 1](#fig1-ijao.5000583){ref-type="fig"}). Metabolic variables (i.e., lactate and base excess) showed a comparable pattern with a most pronounced change postoperatively and a return to baseline levels on postoperative day 3 ([Fig. 1](#fig1-ijao.5000583){ref-type="fig"}). Corresponding courses of the same metabolic parameters of the comparative historical control group are depicted in [Figure 1A](#fig1-ijao.5000583){ref-type="fig"}. Moreover, we observed a stabilization of hemodynamic parameters, as demonstrated by a consistent and maintained increase in MAP postoperatively with a concomitant reduction of catecholamine need at the same time (epinephrine and norepinephrine) ([Fig. 2](#fig2-ijao.5000583){ref-type="fig"}). On postoperative day 3, 72% and 82% of the patients were free from norepinephrine and epinephrine support, respectively. On postoperative day 5, these percentages increased to 82% and 95% for norepinephrine and epinephrine, respectively (data not shown). Interestingly, 15 out of the 39 IE patients initially requiring vasopressor support in their postoperative phase did not require any further vasopressor support 18 hours post surgery (3 patients with high EuroSCORE II between 31--97; 2 patients with mid EuroSCORE II between 16--31; 10 patients with low EuroSCORE II between 0--16).

![(A) CytoSorb group: Levels of IL-6 and IL-8 as well as metabolic parameters (lactate and base excess \[median with IQR\]), throughout the observation period. Values were assessed prior to treatment (baseline), during surgery, immediately after as well as on days 1 and 3 post treatment during CPB. (B) Historical control group: Metabolic parameters (lactate and base excess \[median with IQR\]), throughout the observation period. Values were assessed prior to treatment (baseline), during surgery, immediately after as well as on day 1 and 3 post CPB.](10.5301_ijao.5000583-fig1){#fig1-ijao.5000583}

![(A) CytoSorb group: Mean arterial pressure (MAP), catecholamine doses (norepinephrine and epinephrine) throughout the observation period (median with IQR). Values were assessed prior to treatment (baseline), at end of surgery, at 6, 12, 18 and 36 hours as well as on day 1, 2 and 3 postoperatively. Please note that data sets were not completed for every patient. (B) Historical control group: Mean arterial pressure (MAP), catecholamine doses (norepinephrine and epinephrine) throughout the observation period (median with IQR). Values were assessed prior to treatment (baseline), at end of surgery, at 6, 12, 18 and 36 hours as well as on day 1, 2 and 3 postoperatively.](10.5301_ijao.5000583-fig2){#fig2-ijao.5000583}

The severity of illness in the short-term postoperative period using the APACHE II also showed a trend to improvement from a median of 31 directly post operation to a median of 20 on day 1 post-surgery ([Tab. I](#table1-ijao.5000583){ref-type="table"}). A total of 18 patients were able to be weaned from mechanical ventilation within 24 hours after surgery, whereas 21 patients had a prolonged ventilation ranging from 1 to 12 days. Extracorporeal membrane oxygenation (ECMO) was mandatory in 5 patients for up to 5 days. High grade AKI necessitating CRRT was applied in 16 patients for up to 4 days ([Tab. I](#table1-ijao.5000583){ref-type="table"}).

In the comparative historical control group, 12 patients were able to be weaned from mechanical ventilation within 24 hours after surgery, whereas 16 patients had a prolonged ventilation ranging from 2 to 41 days. Extracorporeal membrane oxygenation (ECMO) was mandatory in 2 patients for up to 8 days. High grade AKI necessitating CRRT was applied in 10 patients for up to 46 days ([Tab. II](#table2-ijao.5000583){ref-type="table"}).

Length of ICU stay in the CytoSorb group ranged between 1 and 32 days (median 5). Of the 39 patient treatments summarized in this case series, 8 patients died during their ICU stay (7 between ICU days 1 and 8, 1 patient on ICU day 32) and 2 patients later died during their hospitalization period ([Tab. I](#table1-ijao.5000583){ref-type="table"}). Of note, the death of these patients could not be attributed to any specific treatment. One patient died from mesenteric ischemia with no option for surgical treatment, 1 patient had therapy withdrawn in accordance with the patient\'s advance directive, 5 patients died of refractory multiple organ failure, and 1 patient with refractory cardiac failure.

The length of ICU stay in the comparative historical control group ranged between 2 and 96 days (median 7.5 days). Of the 28 patient evaluated as a historical control group, 2 patients died during ICU stay (days 8 and 96) ([Tab. II](#table2-ijao.5000583){ref-type="table"})

Intraoperative hemoadsorption treatment appeared to be well-tolerated, without device-related adverse events during or after treatment. No technical problems with the implementation of CytoSorb as part of the CPB circuit were observed.

Discussion {#section4-ijao.5000583}
==========

This retrospective case series reports on the application of the hemoadsorption cartridge CytoSorb during the intraoperative treatment of 39 patients with IE undergoing cardiac surgery with CPB. The clinical and laboratory parameters measured along this case series revealed (i) a consistent balanced control of the inflammatory response postoperatively, shown by a marked reduction of IL-6 and IL-8 plasma levels, (ii) the rapid adjustment of metabolic processes indicated by a normalization of lactate and base excess back to preoperative baseline levels within 3 days and (iii) hemodynamic stability before, during, and after the operation accompanied by a rapid decrease in need for vasopressors.

As circulating proinflammatory mediators like IL-6 and IL-8 play a central role in the development of SIRS and sepsis, the application of hemoadsorption devices represents a potential interesting interventional tool to avoid detrimental cross-talk between mediators, DAMPS and PAMPS with the immune system. CytoSorb has been shown to effectively remove hydrophobic molecules from 5 kDa up to approximately 55 kDa such as cytokines, chemokines, myoglobin and various other substances ([@bibr7-ijao.5000583], [@bibr8-ijao.5000583]). Moreover, cytokine reduction by means of CytoSorb application was reported for critically ill and cardiac surgery patients, as supported by a number of published preclinical and clinical data ([@bibr4-ijao.5000583], [@bibr9-ijao.5000583], [@bibr10-ijao.5000583]). After an initial intraoperative increase of cytokine levels, the application of CytoSorb hemoadsorption in this set of patients was associated with a decrease in the postoperative course. Of note, we are aware of the fact that the standard treatment regimen of these critically ill patients including hydrocortisone and CRRT could also have resulted in an additional decrease of these inflammatory parameters. Despite the exclusively intraoperative use of the cytokine adsorber, a reduction of cytokine levels was observable on postoperative day 1, returning back to preoperative levels on day 3, an effect that could possibly have been supported by the CytoSorb treatment. This long-term effect of even 1 CytoSorb treatment might be explained by the fact that hemoadsorption using CytoSorb might function at the level of the circulating immune effector cells, resulting in decreased activation of NfκB (in neutrophils and Kupffer cells) by a diminished cytokine load in the circulation and a subsequent decrease in cytokine production ([@bibr11-ijao.5000583]).

In addition, removal of substances is concentration-dependent. While low cytokine plasma concentrations are not affected, high cytokine plasma levels are reduced effectively. Supporting this line of argumentation, a recent blinded, randomized controlled trial in cardiosurgical patients with CPB compared (i) the CytoSorb application during CPB with (ii) a control group without hemoadsorption during CPB ([@bibr12-ijao.5000583]). Therefore, for instance, the IL-6 level monitored in the plasma of CPB patients did not exceed 254 pg/mL throughout the measurement duration. It is important to note that these were patients (and procedures) with only moderately increased risk who did not suffer from IE at the time of CPB surgery. In contrast, IE patients in our study undergoing CPB had a much more pronounced IL-6 cytokine release level of up to 5,000 pg/mL post treatment. This relevant difference shows that cytokine adsorption might preferably be effective in patients who are in a state of hyperinflammation (e.g., in infective endocarditis). This notion should be even more underlined as Bernardi et al stated that the authors did not find any differences for IL-6 in patients with or without CytoSorb treatment during CPB ([@bibr12-ijao.5000583]).

The decrease in cytokine levels in our case series was paralleled by a stabilization of hemodynamic parameters, during, and after the operation, as demonstrated by reduced catecholamine support (epinephrine and norepinephrine) and an increase in MAP. This effect has been observed in pre-clinical studies as well as in case report and series ([@bibr4-ijao.5000583], [@bibr5-ijao.5000583], [@bibr9-ijao.5000583], [@bibr13-ijao.5000583]).

Of note, it should be considered that the historical control group in our study showed a markedly lower risk profile as compared to the CytoSorb group as evidenced by the EuroSCORE II. This important limitation of historical case control analyses needs to be taken into account when comparing outcome data of both groups.

An important point to justify such a preventive treatment approach is the proof of potential outcome benefits despite the additional costs associated with Cytosorb treatment. From our perspective, such treatment might result in a mitigated inflammatory response postoperatively and hence preserve organ function and result in faster recovery during the postoperative course. While systematic data on these cost/benefit questions are still lacking, there is preliminary evidence available on improved organ function after CytoSorb use. Next to descriptions of unexpectedly fast hemodynamic stabilization ([@bibr5-ijao.5000583], [@bibr14-ijao.5000583], [@bibr15-ijao.5000583]), there is also a recent report indicating ([@bibr16-ijao.5000583]) a protected vascular barrier function after CytoSorb treatment, which might play an important role in earlier recovery of organ function in systemic hyperinflammation.

Since the question of whether there is a reproducible positive benefit/cost ratio to generally justify preventive CytoSorb treatment in patients with infective endocarditis undergoing cardiac surgery cannot definitely be answered from our case series, it will have to be established in future prospective studies.

Conclusions {#section5-ijao.5000583}
===========

With these clinical data and outcomes from 39 patients suffering from IE and undergoing cardiac surgery with CPB in combination with a CytoSorb adsorption device we were able to confirm and extend the results published earlier ([@bibr5-ijao.5000583]). Treatment with the CytoSorb device was safe and well-tolerated with no device- related adverse events during or after the treatment sessions. Even though clinical experience from this case series looks interesting, it is hard to draw any definite conclusions from this uncontrolled, retrospective, observational trial as to whether the effects seen in these patients were a primary therapy effect of CytoSorb or the consequence of a combination of all conducted treatments. With the insight of this recent case series, randomized controlled trials are warranted to further stress the potential benefits of this new treatment option for IE patients receiving cardiac surgery with CPB.
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